ABOUT TyRx PHARMA INC.
TyRx Pharma, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes implantable combination drug—device products utilizing novel biomaterials, including technology licensed exclusively from Rutgers, The State University of New Jersey. Additionally, TyRx has exclusively licensed from Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center product patents and associated technologies to address the problem of post surgical nosocomial infection. TyRx is deploying its capabilities across a broad range of combination implantable medical-pharmaceutical devices. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TyRx is positioned to be an innovative applications leader in the space.

TyRx CORE COMPETENCIES IN THE EMERGING COMBINATION MEDICAL DEVICE PRODUCT SPACE

• Ability to foresee unmet market need in a rapidly emerging sector
  
  
• Focus on high-value added end products
  
  
• Core competencies in innovative solutions to polymer synthesis + medtech + Rx reformulation
  
  
• Strong cross-functional teams that are not bound by ‘conventional wisdom’
  
  
• Proprietary IP on critical technologies and downstream products